CryoPort (CYRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CYRX SEC filings page.
CryoPort, Inc. (CYRX) reported $186.5M in revenue over the twelve months to Jun 30, 2026, up 12.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cryoport’s 2025 rebound improved gross margin and reduced operating losses, but reported profit still did not translate into positive cash generation.
Earnings quality diverged sharply: FY2025 net income of$78.3M contrasted with operating cash flow of-$8.6M , so the accounting profit was not produced by core cash generation. Because free cash flow remained negative at-$25.0M despite capital expenditures falling4.7% , the improvement points to a non-cash or non-operating earnings component rather than a cash-funded turnaround.
Revenue recovered
The balance sheet was deleveraged: liabilities fell
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CryoPort, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
CryoPort, Inc. has an operating margin of -20.9%, meaning the company loses $21 on every $100 of revenue. This results in a profitability score of 17/100. This is up from -77.6% the prior year.
CryoPort, Inc.'s revenue grew 12.4% year-over-year to $176.2M, a solid pace of expansion. This earns a growth score of 38/100.
CryoPort, Inc.'s current ratio of 2.17 indicates adequate short-term liquidity, earning a score of 63/100. The company can meet its near-term obligations, though with limited headroom.
CryoPort, Inc.'s operations used $8.6M of cash, and capex of $16.4M added to the outflow, for a free cash flow shortfall of $25.0M. This results in a cash flow score of 9/100.
CryoPort, Inc. generates a 15.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 24/100. This is up from -28.5% the prior year.
CryoPort, Inc. scores 1.27, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $688.9M against total assets of $765.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CryoPort, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, CryoPort, Inc. used $0.11 of operating cash (-$8.6M OCF vs $78.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
CryoPort, Inc. reported an operating loss of $36.8M against $2.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CryoPort, Inc. generated $49.0M in revenue in Q2 2026. This represents an increase of 7.7% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.
CryoPort, Inc.'s EBITDA was -$3.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
CryoPort, Inc. reported a net loss of $8.3M in Q2 2026. This represents a decrease of 107.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
CryoPort, Inc. earned -$0.20 per diluted share (EPS) in Q2 2026. This represents a decrease of 109.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
CryoPort, Inc. recorded an outflow of $8.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
CryoPort, Inc. held $269.3M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
CryoPort, Inc.'s gross margin was 46.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.
CryoPort, Inc.'s operating margin was -20.5% in Q2 2026, reflecting core business profitability. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.
CryoPort, Inc.'s net profit margin was -16.9% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 5.2 percentage points. No change is given against Q2 2025: its reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
CryoPort, Inc.'s quarterly ROE was -1.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 22.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Capital Allocation
CryoPort, Inc. invested $4.9M in research and development in Q2 2026. This represents an increase of 17.8% from the same quarter a year earlier. Against the prior quarter it is up 24.2%.
CryoPort, Inc. invested $9.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 109.2% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.
Not reported for Q2 2026.
CYRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.0M+7.7% | $47.8M+16.5% | $45.5M+9.6% | $44.2M+15.4% | $45.5M+14.5% | $41.0M+10.1% | $41.5M | $38.3M-31.8% |
| Cost of Revenue | $26.1M+8.6% | $25.9M+15.6% | $23.7M+8.1% | $22.9M+9.7% | $24.1M+9.2% | $22.4M+0.8% | $22.0M | $20.9M-34.5% |
| Gross Profit | $22.8M+6.8% | $21.9M+17.6% | $21.7M+11.4% | $21.3M+22.3% | $21.4M+21.0% | $18.6M+23.7% | $19.5M | $17.4M-28.1% |
| R&D Expenses | $4.9M+17.8% | $3.9M-0.7% | $4.5M+7.5% | $4.5M+8.8% | $4.1M-11.4% | $3.9M-17.2% | $4.2M | $4.2M-19.3% |
| SG&A Expenses | $28.0M+4.1% | $27.6M+26.1% | $27.3M-2.9% | $26.7M+0.2% | $26.9M-1.2% | $21.9M-21.3% | $28.1M | $26.7M-26.0% |
| Operating Income | -$10.0Mn/m | -$9.6Mn/m | -$10.0Mn/m | -$9.9Mn/m | -$9.6Mn/m | -$7.2Mn/m | -$12.7M | -$13.4Mn/m |
| EBITDA | -$3.5Mn/m | -$3.2M-810.6% | -$3.7Mn/m | -$3.5Mn/m | -$2.4Mn/m | $452Kn/m | -$4.9M | -$5.6Mn/m |
| Interest Expense | $518K-16.2% | $432K-25.9% | $634K+9.5% | $526K-40.4% | $618K-50.2% | $583K-54.3% | $579K | $882K-35.0% |
| Income Tax | $505K+84.3% | $108K-53.8% | $1.1Mn/m | $165K-47.8% | $274K+315.2% | $234K+110.8% | -$134K | $316K-32.9% |
| Net Income | -$8.3M-107.6% | -$10.5Mn/m | -$11.6Mn/m | -$6.9M-962.5% | $108.9Mn/m | -$12.0Mn/m | -$18.7M | $805Kn/m |
| EPS (Basic) | -$0.20-109.4% | -$0.25n/m | -$0.28n/m | -$0.18n/m | $2.13n/m | -$0.28n/m | -$0.42n/m | -$0.02n/m |
| EPS (Diluted) | -$0.20-109.4% | -$0.25n/m | -$0.28n/m | -$0.18n/m | $2.13n/m | -$0.28n/m | -$0.42n/m | -$0.02n/m |
| Diluted Shares (Avg) | 50M+0.4% | 50M-0.1% | N/A | 50M+1.4% | 50M+1.8% | 50M+1.9% | N/A | 49M+1.1% |
CYRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $756.2M-2.3% | $763.6M+9.1% | $765.0M+8.7% | $774.3M+10.3% | $773.9M-9.2% | $699.8M-25.8% | $703.5M-26.5% | $701.8M-29.9% |
| Current Assets | $460.2M-6.0% | $470.5M+14.4% | $476.2M+39.4% | $484.8M+38.4% | $489.5M-2.5% | $411.3M-21.8% | $341.6M-36.2% | $350.3M-36.2% |
| Cash & Equivalents | $269.3M+10.6% | $272.9M+655.9% | $250.5M+633.8% | $255.8M+715.6% | $243.4M+612.1% | $36.1M-8.1% | $34.1M-3.0% | $31.4M-47.3% |
| Short-Term Investments | $127.4M-30.2% | $130.7M-37.1% | $160.7M-25.8% | $165.5M-27.4% | $182.6M-52.0% | $207.9M-47.9% | $216.5M-47.3% | $228.0M-43.9% |
| Inventory | $21.5M-6.6% | $21.8M-6.8% | $23.2M+8.0% | $23.3M-1.0% | $23.0M-2.4% | $23.3M-6.7% | $21.5M-18.0% | $23.6M-19.1% |
| Accounts Receivable | $36.5M+9.1% | $39.0M+37.5% | $33.4M+31.8% | $34.9M-19.7% | $33.4M-16.8% | $28.4M-31.2% | $25.3M-39.9% | $43.5M+2.0% |
| Goodwill | $22.1M+17.9% | $22.1M+5.6% | $22.4M+8.9% | $22.4M-58.5% | $18.7M-64.3% | $21.0M-80.5% | $20.6M-73.1% | $54.1M-63.7% |
| Total Liabilities | $265.5M+2.7% | $268.6M-10.8% | $262.4M-13.0% | $261.1M-7.8% | $258.5M-42.8% | $301.0M-36.0% | $301.6M-35.7% | $283.2M-38.9% |
| Current Liabilities | $221.0M+633.1% | $224.9M+203.8% | $219.0M+239.2% | $30.7M-50.0% | $30.1M-49.7% | $74.0M+51.1% | $64.6M+41.6% | $61.4M+36.8% |
| Non-Current Liabilities | $44.5M-80.5% | $43.8M-80.7% | $43.3M-81.7% | $230.3M+3.9% | $228.4M-41.8% | $227.0M-46.2% | $237.0M-44.0% | $221.8M-47.0% |
| Long-Term Debt | N/A | N/A | N/A | $184.8M+0.6% | $184.5M-48.1% | $184.2M-51.4% | $183.9M-51.4% | $183.6M-51.4% |
| Total Equity | $490.7M-5.5% | $495.0M+24.1% | $502.6M+25.1% | $513.3M+22.6% | $519.1M+29.7% | $398.8M-15.5% | $401.9M-17.8% | $418.6M-22.1% |
| Retained Earnings | -$707.7Mn/m | -$699.4Mn/m | -$688.9Mn/m | -$675.2Mn/m | -$668.2Mn/m | -$769.2Mn/m | -$757.2Mn/m | -$738.5Mn/m |
Not reported in any period shown, so not listed: Long-Term Investments.
CYRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1Mn/m | $3.7Mn/m | $919Kn/m | $2.2M+389.5% | -$7.3Mn/m | -$4.3Mn/m | -$5.5M | $447Kn/m |
| Depreciation & Amortization | $6.6M-9.7% | $6.4M-16.3% | $6.4M-19.5% | $6.4M-18.1% | $7.3M-3.5% | $7.6M+2.4% | $7.9M | $7.8M+13.4% |
| Stock-Based Compensation | $2.4M+17.5% | $2.4M-21.8% | N/A | $2.5M-37.7% | $2.0M-51.3% | $3.1M-34.3% | N/A | $4.1M-32.1% |
| Capital Expenditures | $9.1M+109.2% | $10.0M+215.1% | $5.5M+4.8% | $3.5M-18.5% | $4.4M+14.8% | $3.2M-20.9% | $5.2M | $4.2M-52.7% |
| Free Cash Flow | -$8.0Mn/m | -$6.2Mn/m | -$4.5Mn/m | -$1.3Mn/m | -$11.7Mn/m | -$7.5Mn/m | -$10.7M | -$3.8Mn/m |
| Investing Cash Flow | -$5.8M-102.5% | $18.7M+216.1% | $56K-98.4% | $14.3M-90.7% | $230.0M+1626.9% | $5.9M-8.1% | $3.5M | $153.6M+729.7% |
| Financing Cash Flow | $653Kn/m | $85Kn/m | -$2.2M-207.0% | -$2.9Mn/m | -$15.9Mn/m | -$189K-136.9% | $2.0M | -$155.3Mn/m |
| Share Buybacks | N/A | N/A | $2.0M | $3.7M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
CYRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.6%-0.4pp | 45.9%+0.4pp | 47.8%+0.7pp | 48.2%+2.7pp | 47.0%+2.6pp | 45.4%+5.0pp | 47.0% | 45.5%+2.3pp |
| Operating Margin | -20.5%+0.7pp | -20.1%-2.6pp | -22.1%+8.7pp | -22.4%+12.5pp | -21.2% | -17.5%+29.4pp | -30.8% | -34.9%-4.8pp |
| Net Margin | -16.9% | -22.1%+7.1pp | -25.6%+19.4pp | -15.7%-17.8pp | 239.5% | -29.2%+21.5pp | -45.1% | 2.1%+25.7pp |
| Return on Equity | -1.7%-22.7pp | -2.1%+0.9pp | -2.3%+2.3pp | -1.4%-1.5pp | 21.0%+40.5pp | -3.0%+1.0pp | -4.6% | 0.2%+2.7pp |
| Return on Assets | -1.1%-15.2pp | -1.4%+0.3pp | -1.5%+1.1pp | -0.9%-1.0pp | 14.1%+23.2pp | -1.7%+0.3pp | -2.6% | 0.1%+1.4pp |
| Current Ratio | 2.08-14.2x | 2.09-3.5x | 2.17-3.1x | 15.77+10.1x | 16.24+7.9x | 5.56-5.2x | 5.29-6.4x | 5.70-6.5x |
| Debt-to-Equity | N/A | N/A | N/A | 0.36-0.1x | 0.36-0.5x | 0.46-0.3x | 0.46-0.3x | 0.44-0.3x |
| Liabilities-to-Equity | 0.540.0x | 0.54-0.2x | 0.52-0.2x | 0.51-0.2x | 0.50-0.6x | 0.75-0.2x | 0.75-0.2x | 0.68-0.2x |
| Asset Turnover | 0.060.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.06 | 0.050.0x |
| FCF Margin | -16.3%+9.4pp | -13.1%+5.2pp | -10.0%+15.8pp | -2.9%+7.0pp | -25.7%+4.0pp | -18.3%+1.2pp | -25.8% | -9.9%+9.6pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CryoPort, Inc. CYRX | FY2025 | $176.2M | $78.3M | 44.4% | $901.0M | 35/100 |
| Radiant Logistics, Inc. RLGT | FY2026 | $934.4M | $18.8M | 2.0% | $413.9M | 47/100 |
| Forward Air Corp FWRD | FY2025 | $2.5B | -$107.8M | -4.3% | $509.4M | 30/100 |
| Pitney Bowes Inc. PBI | FY2025 | $1.9B | $144.7M | 7.6% | $2.4B | 23/100 |
| BingEx Limited FLX | FY2025 | $570.9M | $15.6M | 2.7% | $109.0M | 39/100 |
| Proficient Auto Logistics, Inc. PAL | FY2025 | N/A | -$36.0M | N/A | $71.5M | — |
Where CryoPort, Inc. Ranks
Frequently Asked Questions
What is CryoPort, Inc.'s annual revenue?
CryoPort, Inc. (CYRX) reported $176.2M in total revenue for fiscal year 2025. This represents a 12.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CryoPort, Inc.'s revenue growing?
CryoPort, Inc. (CYRX) revenue grew by 12.4% year-over-year, from $156.8M to $176.2M in fiscal year 2025.
Is CryoPort, Inc. profitable?
No, CryoPort, Inc. (CYRX) reported a net loss of $37.4M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $78.3M, with a net profit margin of 44.4%.
What is CryoPort, Inc.'s EBITDA?
CryoPort, Inc. (CYRX) had EBITDA of -$9.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CryoPort, Inc.'s gross margin?
CryoPort, Inc. (CYRX) had a gross margin of 47.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is CryoPort, Inc.'s operating margin?
CryoPort, Inc. (CYRX) had an operating margin of -20.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is CryoPort, Inc.'s net profit margin?
CryoPort, Inc. (CYRX) had a net profit margin of 44.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is CryoPort, Inc.'s return on equity (ROE)?
CryoPort, Inc. (CYRX) has a return on equity of 15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CryoPort, Inc.'s free cash flow?
CryoPort, Inc. (CYRX) recorded an outflow of $25.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CryoPort, Inc.'s operating cash flow?
CryoPort, Inc. (CYRX) recorded an outflow of $8.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CryoPort, Inc.'s total assets?
CryoPort, Inc. (CYRX) had $765.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CryoPort, Inc.'s capital expenditures?
CryoPort, Inc. (CYRX) invested $16.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does CryoPort, Inc. spend on research and development?
CryoPort, Inc. (CYRX) invested $17.0M in research and development during fiscal year 2025.
What is CryoPort, Inc.'s current ratio?
CryoPort, Inc. (CYRX) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.
What is CryoPort, Inc.'s liabilities-to-equity ratio?
CryoPort, Inc. (CYRX) had a liabilities-to-equity ratio of 0.52 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is CryoPort, Inc.'s return on assets (ROA)?
CryoPort, Inc. (CYRX) had a return on assets of 10.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CryoPort, Inc.'s P/E ratio?
CryoPort, Inc. (CYRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $901.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CryoPort, Inc.'s price-to-sales ratio?
CryoPort, Inc. (CYRX) trades at 4.8x sales, its market capitalization divided by $186.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $901.0M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CryoPort, Inc.'s Altman Z-Score?
CryoPort, Inc. (CYRX) has an Altman Z-Score of 1.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CryoPort, Inc.'s Piotroski F-Score?
CryoPort, Inc. (CYRX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CryoPort, Inc.'s earnings high quality?
For every $1 of reported earnings, CryoPort, Inc. (CYRX) used $0.11 of operating cash (-$8.6M OCF vs $78.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CryoPort, Inc. cover its interest payments?
CryoPort, Inc. (CYRX) reported an operating loss of $36.8M against $2.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is CryoPort, Inc.?
CryoPort, Inc. (CYRX) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.